Condition: Metastatic Gastric Adenocarcinoma · Second Line · Chemotherapy · Sponsor: National Health Research Institutes, Taiwan
Primary Objectives * In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) * In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives * To evaluate disease control rate (DCR) * To evaluate progression-free survival (PFS) * To evaluate overall survival (OS) * To assess the safety profile * To study the blood biomarkers
This description comes directly from the study's public registry record.
Chien-Ya Hung, BS · +886-3-7206166 · 951106@nhri.edu.tw
Nai-Jung Chiang, MD-PhD · +886-9-58925290 · njchiang@nhri.edu.tw
Always discuss trial participation with your own doctor first.
| Taipei Veterans General Hospital | Taipei, Taiwan/Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05927857